Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + Venetoclax in R/R AML or High-Risk MDS
NCT03067571Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2017
- Primary completion
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), Precursor T-cell lymphoblastic leukemia/lymphoma (T-LBL/ALL), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2017; status: terminated.
02
Drugs
daratumumab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Precursor T-cell lymphoblastic leukemia/lymphoma (T-LBL/ALL)
Beyond the preview
Go deeper on NCT03067571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03067571.